App-Quantinova.ai

Differential Expression Patterns of the TNF Pathway in Dorsolateral Prefrontal Cortical Regions (BA9/BA46) in Schizophrenia and Mood Disorder

Tharini Ketharanathan - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Schizophrenia

N/A

Neuroanatomical Correlates of Psychotic-Like Experiences Assessed in 2,695 Individuals via the ENIGMA Consortium

Mathilde Antoniades - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Schizophrenia

N/A

Preliminary Results of a Transcranial Direct Current Stimulation Intervention in Military Patients With Posttraumatic Stress Disorder, Anxiety and Aggression

Fenne Smits - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Post traumatic stress disorder

N/A

Relationship Between Threat- and Reward-Related Brain Structure and Symptom Dimensions of Anxiety and Depression

Anna Cichocki - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

N/A

Defining Targeted Projection Patterns in Thalamus Using Diffusion Weighted Imaging

Amber Howell - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Neural Representation of Threat Features and Behavior in a Human Approach-Avoidance Conflict Anxiety Task

Aslan Abivardi - Society of Biological Psychiatry (SOBP) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

Identification of microbial-derived HLA-bound peptides in melanoma

Adi Nagler - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

Toni Choueiri - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

Cabozantinib

Gene expression analysis of immune checkpoint therapy in mouse tumor models reveals similarities and differences in immune cell populations and functional processes that reflect response to treatment

Dominic Pearce - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

Immunopeptidome changes mediated by a novel ERAP1 inhibitor leads to tumor growth inhibition

Peter Joyce - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action

Michelle Morrow - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

FS118

Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

Francesca Aroldi - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Optimization of a GM3-containing liposomal vaccine that delivers antigen to CD169+ splenic macrophages

Maarten Nijen Twilhaar - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

E-0704

Prognostic value of tumor size varies by treatment in a meta-analysis of 15 randomized clinical trials in advanced non-small cell lung cancer across immunotherapy, TKI, and chemotherapy regimens

Jacqueline Buros - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Mavrilimumab, a human monoclonal antibody targeting GM-CSFRα, inhibits polarization to myeloid-derived suppressor cells (MDSCs) that express PD-L1 and restores T-cell proliferation in vitro

Luis Carvajal - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Mavrilimumab

Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Antonio Jimeno - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Cyclophosphamide

Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma

Jeffrey Weber - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Ipilimumab

Inhibition of AKT signaling during expansion of TCR-engineered T-cells from patient leukocyte material generates SPEAR T-cells with enhanced functional potential in vitro

Katerina Mardilovich - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

Mohamed Eltahir - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

Rituximab

Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

Kevin Harrington - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon

Filters

45280 Abstracts